Clinical Trial Trends: Cell Therapy

Cell Therapy has become a central focus in oncology research, with thousands of trials exploring its potential across hematologic and solid tumors. Since the first CAR-T product was approved in 2017, the field has expanded to include T-cell receptor (TCR) therapies, tumor-infiltrating lymphocytes (TILs), and natural killer (NK) cell platforms. As of early 2024, more than 5,600 interventional cancer Cell Therapy trials have been registered globally, with over 2,300 currently active.¹

CAR-T therapies targeting CD19 and BCMA have led the way in hematologic malignancies, with several products now approved across multiple indications.¹ TIL therapies, such as lifileucel for metastatic melanoma, have opened the door to solid tumor applications, while TCR-based therapies are advancing in rare cancers like synovial sarcoma. Despite these successes, challenges remain. Cell persistence, manufacturing complexity, and toxicity management continue to shape trial design and execution.

Sponsors are increasingly exploring allogeneic platforms to reduce production timelines and costs. These off-the-shelf therapies offer scalability but require careful immunogenicity monitoring. Trials are also investigating combination strategies, pairing cell therapies with checkpoint inhibitors or radiation to enhance efficacy. The use of real-world data and adaptive designs is helping sponsors refine protocols and improve patient selection. 

Geographically, trial activity is concentrated in North America, Europe, and China, with growing interest in expanding access through decentralized models. Regulatory agencies are adapting to the complexity of Cell Therapy trials, offering expedited pathways and clearer guidance on manufacturing and safety standards. 

This article reviews the current Cell Therapy trial landscape, including trial status, geographic distribution, patient segments, and therapeutic focus. It also outlines how Precision for Medicine supports sponsors in executing these highly specialized studies

Cell Therapy Clinical Trials by Status 

The status distribution highlights active exploration in cell-based treatments. Sponsors may face competition for patient enrollment and site availability. 

Cell Therapy Trials by Status 

Citeline Trialtrove® – 07OCT2025 

Cell Therapy Trials by Start Date 

Cell therapy trial initiations have surged in recent years. Post-2020 growth aligns with advances in manufacturing and delivery technologies. 

Planned & Ongoing Cell Therapy Trials by Start Date 

Citeline Trialtrove® – 07OCT2025

Cell Therapy Trials by Country  

Cell therapy trials are concentrated in key global regions. Sponsors should consider regional expertise in cell handling and delivery. 

Planned & Ongoing Cell Therapy Trials by Site Country 

Chart Caption: Citeline Trialtrove® – 07OCT2025 

Cell Therapy Trials by Therapeutic Area 

Therapeutic area trends show strong interest in oncology. Precision targeting enhances cell therapy efficacy and safety. 

Planned & Ongoing Cell Therapy Trials by Therapeutic Area 

Citeline Trialtrove® – 07OCT2025 

Cell Therapy Trials by Indication  

Leukemia, lymphoma, and solid tumors dominate trial activity. Targeted indications benefit from personalized cell therapy approaches.  

Planned & Ongoing Cell Therapy Trials by Indication 

 
Citeline Trialtrove® – 07OCT2025 

Cell Therapy Trials by Phase  

Cell therapy trials are heavily weighted toward early phases. Phase distribution reflects the experimental nature of cell-based treatments. 

Planned & Ongoing Cell Therapy Trials by Phase 

Citeline Trialtrove® – 07OCT2025

Precision's Expertise in Cell Therapy Research  

Precision for Medicine’s infrastructure supports scalable cell therapy programs. We partner with sponsors to navigate complex startup requirements. 

Cell Therapy Trial Starts  

Precision for Medicine has launched multiple cell therapy trials. 

Precision for Medicine's Cell Therapy Trials by Start Date 

Citeline Trialtrove® – 07OCT2025 

Precision's Reach in Cell Therapy Research  

Precision’s cell therapy trials span key global regions. North America and Europe are primary trial locations. 

Precision for Medicine's Cell Therapy Trials by Site Country 

Citeline Trialtrove® – 07OCT2025 

Cell Therapy Trials by Phase  

Our portfolio includes a strong emphasis on early development. We guide cell therapies from first-in-human to pivotal trials. 

Precision for Medicine's Cell Therapy Trials by Phase 

Citeline Trialtrove® – 07OCT2025 

Precision's Experience by Therapeutic Area 

Cancer remains a central focus of our cell therapy portfolio. We are expanding into autoimmune and regenerative medicine. 

Precision for Medicine's Cell Therapy Trials by Therapeutic Area 

Citeline Trialtrove® – 07OCT2025 

Precision Cell Therapy Trials by Top Indications 

Our cell therapy portfolio includes studies in hematologic and solid tumors. 

Precision for Medicine's Cell Therapy Trials by Top Indications 

 Citeline Trialtrove® – 07OCT2025 

Understanding the Difference Precision Makes  

Cell Therapy trials require careful coordination across manufacturing, logistics, and clinical operations. Precision for Medicine works with sponsors to manage these complexities, ensuring trials are executed with consistency and control. Our teams bring experience in oncology and advanced therapeutics, helping sponsors navigate the unique demands of Cell Therapy development.  

Explore the ways Precision is pushing the limits in cell therapy research >

References

‌